0001415889-24-015590.txt : 20240605
0001415889-24-015590.hdr.sgml : 20240605
20240605165941
ACCESSION NUMBER: 0001415889-24-015590
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilbert Halley E
CENTRAL INDEX KEY: 0001601360
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 241022790
MAIL ADDRESS:
STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC.
STREET 2: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
form4-06052024_080637.xml
X0508
4
2024-06-03
0001649094
Vaxcyte, Inc.
PCVX
0001601360
Gilbert Halley E
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
true
false
false
false
1
Common Stock
2024-06-03
4
M
0
18200
5.35
A
23825
D
Common Stock
2024-06-03
4
S
0
18200
73
D
5625
D
Stock Option (Right to Buy)
5.35
2024-06-03
4
M
0
18200
0
D
2030-04-17
Common Stock
18200
30374
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
Option is fully vested and exercisable.
Reporting Person has transferred 30,374 vested stock options to Reporting Person's ex-spouse pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Accordingly, Reporting Person will not report beneficial ownership of or dispositions or acquisitions of the underlying shares in future Section 16(a) filings.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-06-05